This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer's (PFE) Comirnaty Booster Dose Achieves 95.6% Efficacy
by Zacks Equity Research
Pfizer (PFE) and BioNTech announce promising data from a late-stage study evaluating the booster dose of their COVID-19 vaccine, Comirnaty.
Fastly, PagerDuty, Johnson & Johnson, Moderna and Pfizer highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Fastly, PagerDuty, Johnson & Johnson, Moderna and Pfizer highlighted as Zacks Bull and Bear of the Day
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
What's in Store for Teladoc Health's (TDOC) Earnings in Q3?
by Zacks Equity Research
Teladoc Health (TDOC) is likely to report a strong revenue outperformance for the third quarter, driven by broad-based momentum across its business and a sharp acceleration in visit-volume growth.
Novavax (NVAX) Down on COVID Jab-Manufacturing Problem Reports
by Zacks Equity Research
Novavax's (NVAX) shares fall on reports of the company's manufacturing problems related to its COVID-19 vaccine candidate.
FDA Approves JNJ & MRNA's COVID-19 Boosters & Mixing of Doses
by Indrajit Bandyopadhyay
The FDA authorizes booster doses of COVID-19 vaccines of JNJ and MRNA. It also authorizes a heterologous boosting option which will allow administration of booster dose of any available vaccine irrespective of the primary vaccination regimen.
Teladoc (TDOC) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Robust customer uptake and novel innovations are likely to have contributed to growth for Teladoc (TDOC).
The Zacks Analyst Blog Highlights: Microsoft, Mastercard, Pfizer, PepsiCo and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Mastercard, Pfizer, PepsiCo and Merck
Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.
Top Analyst Reports for Microsoft, Mastercard & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Mastercard Incorporated (MA), and Pfizer Inc. (PFE).
Are Investors Undervaluing Pfizer (PFE) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Atea (AVIR) Plunges on Oral COVID Candidate Study Failure
by Zacks Equity Research
Atea (AVIR) is developing an oral drug candidate, AT-527, as a potential treatment for COVID-19 in outpatients as well as hospitalized settings in several studies.
Roche (RHHBY) 9M21 Sales Grow on Strong COVID-19 Tests, View Up
by Zacks Equity Research
Roche (RHHBY) posts an encouraging performance in the third quarter and the first nine months of 2021 driven by demand for coronavirus tests due to the Delta variant and recovery in pharma sales.
Valneva (VALN) Reports Positive Data From COVID Vaccine Study
by Zacks Equity Research
Valneva's (VALN) shares surge after its COVID vaccine demonstrates superiority over AstraZeneca's COVID vaccine in a phase III study.
J&J (JNJ) Beats on Q3 Earnings, Misses on Sales, Ups EPS View
by Zacks Equity Research
J&J (JNJ) reports mixed third-quarter earnings. It beats estimates for earnings but misses the same for sales. It raises its earnings guidance range for the year.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $41.32, marking a -0.41% move from the previous day.
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
Pfizer (PFE) Gets CHMP Nod for JAK Inhibitor Abrocitinib
by Zacks Equity Research
The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.
J&J, Moderna COVID-19 Booster Jabs Near FDA Authorization
by Zacks Equity Research
The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.
Novavax (NVAX) Lags in COVID Vaccine Race: Will It Gather Pace?
by Zacks Equity Research
Novavax (NVAX) is progressing well with its COVID-19 and flu vaccines. However, it is lagging in the COVID-19 vaccine space. Let us see how the company is likely to perform going forward.
Deciphera (DCPH) Thrives on Qinlock, Overdependence a Woe
by Zacks Equity Research
Deciphera's (DCPH) Qinlock is approved for treating advanced gastrointestinal stromal tumors. The drug has seen solid uptake since its launch. Heavy dependence on Qinlock for growth remains a concern.
Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition
by Zacks Equity Research
Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.
The Zacks Analyst Blog Highlights: Southwest Airlines, Delta Air Lines, Moderna, Pfizer and BioNTech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Southwest Airlines, Delta Air Lines, Moderna, Pfizer and BioNTech
Best Single Trading Day in Months for Dow, Nasdaq, S&P
by Mark Vickery
The indexes had been trying to turn around a steep drop to the start of the week, and finally managed on Thursday.